Download PDF
Fortschr Neurol Psychiatr 2001; 69(12): 569-580
DOI: 10.1055/s-2001-19181
Originalarbeit
Georg Thieme Verlag Stuttgart · New York

Klinische Relevanz und Behandlungsmöglichkeiten von Rapid Cycling bei Patienten mit bipolarer affektiver Störung

Clinical Relevance and Treatment Possibilities of Rapid Cycling in Patients with Bipolar DisorderB.  Amann1 , R.  Stampfer1 , F.  Schmidt1 , P.  Mikhaiel1 , B.  Hummel1 , A.  Sterr1 , M.  Schäfer1 , H.  Grunze1
  • 1Psychiatrische Universitätsklinik der LMU München (Direktor: Prof. Dr. med. H. J. Möller)
Further Information

Publication History

Publication Date:
19 December 2001 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Nach den derzeit gültigen diagnostischen Leitlinien des ICD-10 finden Subtypen des bipolaren Spektrums syndromorientiert und in Bezug auf den Verlauf nur randständig Berücksichtigung. Im Gegensatz dazu hat im amerikanischen DSM-IV eine Unterteilung von Bipolar-I-Störung (ausgeprägte manische und depressive Episoden) und Bipolar-II-Störung (hypomanische und depressive Episoden) bereits 1994 Eingang gefunden. Auch wird eine differenzielle Verlaufsbeobachtung der Erkrankung mit klinischer Relevanz, wie das Rapid Cycling (RC), mit einbezogen. Dabei handelt es sich um einen Verlauf einer bipolaren Erkrankung mit mindestens 4 affektiven Episoden in einem Jahr. Für diesen wird ebenso wie bei gemischten Episoden und einem atypischen Beginn (initiale Depression) bei Patienten mit einer bipolaren Erkrankung ein schlechteres Ansprechen auf die Standardtherapie Lithium postuliert. Aufgrund dessen sind medikamentöse Alternativen und zusätzliche Therapieansätze hinsichtlich einer Phasenprophylaxe aus klinischer Sicht dringend notwendig; diese werden im Beitrag auf aktuellem Stand dargestellt und diskutiert. Ebenso werden mit RC assoziierte Parameter wie gehäuftes Auftreten bei Frauen, hypothyreote Stoffwechsellage, bipolarer Subtyp, COMT-Allel, Einfluss durch Schlaf und Induktion durch Antidepressiva dargestellt.

Abstract

In the actual version of the WHO diagnostic guidelines, the ICD-10, subtypes of bipolar disorder are not specified, in contrast to the American DSM-IV, where bipolar disorder has already been differentiated in bipolar I (severe manic and depressive episodes) and bipolar II disorder (depressive and hypomanic episodes). Furthermore, aspects of the longitudinal course of the illness, like rapid cycling (RC), are reflected as well. Rapid cycling is defined as four or more affective episodes within one year of the illness. It has been postulated that rapid cycling is related with a poor response to lithium, to the same extent as mixed episodes or an atypical onset (depressive episode first) of the disease. Here, the current status of alternative pharmacological and supportive therapy of rapid cycling is presented and discussed. Furthermore, the article also displays biological parameters associated with rapid cycling like higher prevalence in women, hypothyreoidism, subtype of bipolar disorder, COMT-allele, influence of sleep or risk of antidepressant induced cycling.

Literatur

  • 1 Dunner D L, Fieve R R. Clinical factors in lithium carbonate prophylaxis failure.  Arch Gen Psychiatry. 1974;  30 229-233
    CrossrefPubMedGoogle Scholar
  • 2 American Psychiatric Association .Diagnostisches und statistisches Manual psychischer Störungen DSM-IV. Göttingen, Bern, Toronto, Seattle: Hogrefe 1996
    Google Scholar
  • 3 World Health Organization .The ICD-10 Classification of Mental and behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: WHO 1992
    Google Scholar
  • 4 Kukopulos A, Caliari B, Tundo A, Minnai G, Floris G, Reginaldi D. et al . Rapid cyclers, temperament, and antidepressants.  Compr Psychiatry. 1983;  24 249-258
    CrossrefPubMedGoogle Scholar
  • 5 Goodwin F K, Jamison K R. Manic-depressive illness. New York: Oxford University Press 1990
    Google Scholar
  • 6 Bauer M S, Calabrese J, Dunner D L, Post R, Whybrow P C, Gyulai L. et al . Multisite data reanalysis of the validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV.  Am J Psychiatry. 1994;  151 506-515
    PubMedGoogle Scholar
  • 7 Frye M A, Altshuler L L, Szuba M P, Finch N N, Mintz J. The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay.  J Clin Psychiatry. 1996;  57 17-21
    PubMedGoogle Scholar
  • 8 Alarcon R D. Rapid cycling affective disorders: a clinical review.  Compr Psychiatry. 1985;  26 522-540
    CrossrefPubMedGoogle Scholar
  • 9 Wehr T A, Sack D A, Rosenthal N E, Cowdry R W. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients.  Am J Psychiatry. 1988;  145 179-184
    PubMedGoogle Scholar
  • 10 Tondo L, Baldessarini R J. Rapid cycling in women and men with bipolar manic-depressive disorders.  Am J Psychiatry. 1998;  155 1434-1436
    PubMedGoogle Scholar
  • 11 Leibenluft E, Ashman S B, Feldman N S, Yonkers K A. Lack of relationship between menstrual cycle phase and mood in a sample of women with rapid cycling bipolar disorder.  Biol Psychiatry. 1999;  46 577-580
    CrossrefPubMedGoogle Scholar
  • 12 Feldman-Naim S, Turner E H, Leibenluft E. Diurnal variation in the direction of mood switches in patients with rapid-cycling bipolar disorder.  J Clin Psychiatry. 1997;  58 79-84
    PubMedGoogle Scholar
  • 13 Leibenluft E, Albert P S, Rosenthal N E, Wehr T A. Relationship between sleep and mood in patients with rapid-cycling bipolar disorder.  Psychiatry Res. 1996;  63 161-168
    CrossrefPubMedGoogle Scholar
  • 14 Ashman S B, Monk T H, Kupfer D J, Clark C H, Myers F S, Frank E. et al . Relationship between social rhythms and mood in patients with rapid cycling bipolar disorder.  Psychiatry Res. 1999;  86 1-8
    CrossrefPubMedGoogle Scholar
  • 15 Bauer M S, Whybrow P C, Winokur A. Rapid cycling bipolar affective disorder. I. Association with grade I hypothyroidism.  Arch Gen Psychiatry. 1990;  47 427-432
    PubMedGoogle Scholar
  • 16 Cho J T, Bone S, Dunner D L, Colt E, Fieve R R. The effect of lithium treatment on thyroid function in patients with primary affective disorder.  Am J Psychiatry. 1979;  136 115-116
    PubMedGoogle Scholar
  • 17 Cowdry R W, Wehr T A, Zis A P, Goodwin F K. Thyroid abnormalities associated with rapid-cycling bipolar illness.  Arch Gen Psychiatry. 1983;  40 414-420
    CrossrefPubMedGoogle Scholar
  • 18 Coryell W, Endicott J, Keller M. Rapidly cycling affective disorder. Demographics, diagnosis, family history, and course.  Arch Gen Psychiatry. 1992;  49 126-131
    PubMedGoogle Scholar
  • 19 Bauer M, Hellweg R, Baumgartner A. Hochdosierte Thyroxinbehandlung bei therapie- und prophylaxeresistenten Patienten mit affektiven Psychosen.  Nervenarzt. 1998;  69 1019-1022
    CrossrefPubMedGoogle Scholar
  • 20 Bauer M S, Whybrow P C. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study.  Arch Gen Psychiatry. 1990;  47 435-440
    CrossrefPubMedGoogle Scholar
  • 21 Baumgartner A, Bauer M, Hellweg R. Treatment of intractable non-rapid cycling bipolar affective disorder with high-dose thyroxine: an open clinical trial.  Neuropsychopharmacology. 1994;  10 183-189
    PubMedGoogle Scholar
  • 22 Sack D A, James S P, Rosenthal N E, Wehr T A. Deficient nocturnal surge of TSH secretion during sleep and sleep deprivation in rapid-cycling bipolar illness.  Psychiatry Res. 1988;  23 179-191
    CrossrefPubMedGoogle Scholar
  • 23 Johnston A M, Eagles J M. Lithium-associated clinical hypothyroidism. Prevalence and risk factors.  Br J Psychiatry. 1999;  175 336-339
    PubMedGoogle Scholar
  • 24 Gutierrez B, Bertranpetit J, Guillamat R, Valles V, Arranz M J, Kerwin R. et al . Association analysis of the catechol O-methyltransferase gene and bipolar affective disorder.  Am J Psychiatry. 1997;  154 113-115
    PubMedGoogle Scholar
  • 25 Kunugi H, Vallada H P, Hoda F, Kirov G, Gill M, Aitchison K J. et al . No evidence for an association of affective disorders with high- or low-activity allele of catechol-o-methyltransferase gene.  Biol Psychiatry. 1997;  42 282-285
    CrossrefPubMedGoogle Scholar
  • 26 Kirov G, Murphy K C, Arranz M J, Jones I, McCandles F, Kunugi H. et al . Low activity allele of catechol-O-methyltransferase gene associated with rapid cycling bipolar disorder.  Mol Psychiatry. 1998;  3 342-345
    CrossrefPubMedGoogle Scholar
  • 27 Papolos D F, Veit S, Faedda G L, Saito T, Lachman H M. Ultra-ultra rapid cycling bipolar disorder is associated with the low activity catecholamine-O-methyltransferase allele.  Mol Psychiatry. 1998;  3 346-349
    CrossrefPubMedGoogle Scholar
  • 28 Geller B, Cook E H. Ultradian rapid cycling in prepubertal and early adolescent bipolarity is not in transmission disequilibrium with val/met COMT alleles.  Biol Psychiatry. 2000;  47 605-609
    CrossrefPubMedGoogle Scholar
  • 29 Juckel G, Hegerl U, Mavrogiorgou P, Gallinat J, Mager T, Tigges P. et al . Clinical and biological findings in a case with 48-hour bipolar ultrarapid cycling before and during valproate treatment.  J Clin Psychiatry. 2000;  61 585-593
    PubMedGoogle Scholar
  • 30 Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L. Course of the manic-depressive cycle and changes caused by treatment.  Pharmakopsychiatr Neuropsychopharmakol. 1980;  13 156-167
    PubMedGoogle Scholar
  • 31 Tondo L, Laddomada P, Serra G, Minnai G, Kukopulos A. Rapid cyclers and antidepressants.  Int Pharmacopsychiatry. 1981;  16 119-123
    PubMedGoogle Scholar
  • 32 Sachs G S. Treatment-resistant bipolar depression.  Psychiatr Clin North Am. 1996;  19 215-236
    CrossrefPubMedGoogle Scholar
  • 33 Srisurapanont M, Yatham L N, Zis A P. Treatment of acute bipolar depression: a review of the literature.  Can J Psychiatry. 1995;  40 533-544
    PubMedGoogle Scholar
  • 34 Frances A J, Kahn D A, Carpenter D, Docherty J P, Donovan S L. The Expert Consensus Guidelines for treating depression in bipolar disorder.  J Clin Psychiatry. 1998;  59 (Suppl 4) 73-79
    PubMedGoogle Scholar
  • 35 Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants.  Br J Psychiatry. 1994;  164 549-550
    PubMedGoogle Scholar
  • 36 Calabrese J R, Rapport D J, Kimmel S E, Shelton M D. Controlled trial in bipolarl I depression: focus on switch rates and efficacy.  Eur Neuropsychopharmacol. 1999;  9 (Suppl 4) S109-S112
    CrossrefPubMedGoogle Scholar
  • 37 Möller H-J, Grunze H. Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants?.  Eur Arch Psychiatry Clin Neurosci. 2000;  250 57-68
    CrossrefPubMedGoogle Scholar
  • 38 Sachs G S, Printz D J, Kahn D A, Carpenter D, Docherty J P. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000.  Postgrad Med Spec Report. 2000;  1-104
    PubMedGoogle Scholar
  • 39 Thase M E, Sachs G S. Bipolar depression: Pharmacotherapy and related therapeutic strategies.  Biol Psychiatry. 2000;  48 558-572
    CrossrefPubMedGoogle Scholar
  • 40 Kukopulos A, Reginaldi D. Recurrence of manic-depressive episodes during lithium treatment. In: Johnson FN (Hrsg). Handbook of Lithium Therapy. Lancaster: MTP Press 1980
    Google Scholar
  • 41 Baldessarini R J, Tondo L, Floris G, Hennen J. Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients.  J Affect Disord. 2000;  61 13-22
    CrossrefPubMedGoogle Scholar
  • 42 Maj M, Magliano L, Pirozzi R, Marasco C, Guarneri M. Validity of rapid cycling as a course specifier for bipolar disorder.  Am J Psychiatry. 1994;  151 1015-1019
    PubMedGoogle Scholar
  • 43 Kilzieh N, Akiskal H S. Rapid-cycling bipolar disorder. An overview of research and clinical experience.  Psychiatr Clin North Am. 1999;  22 585-607
    CrossrefPubMedGoogle Scholar
  • 44 Swann A C, Secunda S K, Katz M M, Koslow S H, Maas J W, Chang S. et al . Lithium treatment of mania: clinical characteristics, specificity of symptom change, and outcome.  Psychiatry Res. 1986;  18 127-141
    CrossrefPubMedGoogle Scholar
  • 45 Secunda S K, Katz M M, Swann A, Koslow S H, Maas J W, Chuang S. et al . Mania. Diagnosis, state measurement and prediction of treatment response.  J Affect Disord. 1985;  8 113-121
    CrossrefPubMedGoogle Scholar
  • 46 Calabrese J R, Fatemi S H, Kujawa M, Woyshville M J. Predictors of response to mood stabilizers.  J Clin Psychopharmacol. 1996;  16 24S-31S
    PubMedGoogle Scholar
  • 47 Janicak P G, Newman R, Davis J M. Advances in the treatment of mania related disorders: a reappraisal.  Psychiatry Ann. 1992;  22 92-103
    PubMedGoogle Scholar
  • 48 Post R M. Non-lithium treatment for bipolar disorder.  J Clin Psychiatry. 1990;  51 Suppl 9-16
    PubMedGoogle Scholar
  • 49 Stoll A L, Banov M, Kolbrener M, Mayer P V, Tohen M, Strakowski S M. et al . Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders.  J Clin Psychopharmacol. 1994;  14 311-313
    PubMedGoogle Scholar
  • 50 Grof P, Angst J, Karasek M, Keitner G. Patient selection for long-term lithium treatment in clinical practice.  Arch Gen Psychiatry. 1979;  36 894-897
    PubMedGoogle Scholar
  • 51 Calabrese J R, Woyshville M J, Kimmel S E, Rapport D J. Predictors of valproate response in bipolar rapid cycling.  J Clin Psychiatry. 1993;  13 280-283
    PubMedGoogle Scholar
  • 52 Herridge P L, Pope H G. Treatment of bulimia and rapid-cycling bipolar disorder with sodium valproate: a case report.  J Clin Psychopharmacol. 1985;  5 229-230
    PubMedGoogle Scholar
  • 53 McElroy S L, Keck P E, Pope H G, Hudson J I. Valproate in the treatment of rapid-cycling bipolar disorder.  J Clin Psychopharmacol. 1988;  8 275-279
    PubMedGoogle Scholar
  • 54 Sovner R. The use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders.  J Clin Psychiatry. 1989;  50 Suppl 40-43
    PubMedGoogle Scholar
  • 55 Calabrese J R, Delucchi G A. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder.  Am J Psychiatry. 1990;  147 431-434
    PubMedGoogle Scholar
  • 56 Calabrese J R, Markovitz P J, Kimmel S E, Wagner S C. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients.  J Clin Psychopharmacol. 1992;  12 53S-56S
    PubMedGoogle Scholar
  • 57 Grunze H, Amann B, Schäfer M, Sterr A, Schaerer L, Wild E. et al . Wirksamkeit, Verträglichkeit und Praktikabilität von Valproat-Miniretardtabletten bei bipolaren affektiven Störungen.  Fortschr Neurol Psychiatr. 2000;  68 496-502
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 Schaff M R, Fawcett J, Zajecka J M. Divalproex sodium in the treatment of refractory affective disorders.  J Clin Psychiatry. 1993;  54 380-384
    PubMedGoogle Scholar
  • 59 Jacobsen F M. Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome.  J Clin Psychiatry. 1993;  54 229-234
    PubMedGoogle Scholar
  • 60 Sharma V, Persad E, Mazmanian D, Karunaratne K. Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium.  Can J Psychiatry. 1993;  38 137-139
    PubMedGoogle Scholar
  • 61 Denicoff K D, Smith-Jackson E E, Bryan A L, Ali S O, Post R M. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder.  Am J Psychiatry. 1997;  154 1456-1458
    PubMedGoogle Scholar
  • 62 Schneider A L, Wilcox C S. Divalproate augmentation in lithium-resistant rapid cycling mania in four geriatric patients.  J Affect Disord. 1998;  47 201-205
    CrossrefPubMedGoogle Scholar
  • 63 Lepkifker E, Iancu I, Dannon P, Ziv R, Kotler M. Valproic acid in ultra-rapid cycling: a case report.  Clin Neuropharmacol. 1995;  18 72-75
    PubMedGoogle Scholar
  • 64 Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H. et al . Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study.  Psychopharmacology. 1979;  66 211-217
    CrossrefPubMedGoogle Scholar
  • 65 Greil W, Ludwig-Mayerhofer W, Erazo N, Schöchlin C, Schmidt S, Engel R R. et al . Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study.  J Affect Disord. 1997;  43 151-161
    CrossrefPubMedGoogle Scholar
  • 66 Elphick M. An open clinical trial of carbamazepine in treatment-resistant bipolar and schizo-affective psychotics.  Br J Psychiatry. 1985;  147 198-200
    PubMedGoogle Scholar
  • 67 Levy J M, Remick R A. Clinical aspects and treatment of rapid cycling mood disorders.  Can J Psychiatry. 1986;  31 436-441
    PubMedGoogle Scholar
  • 68 Di Costanzo E, Schifano F. Lithium alone or in combination with carbamazepine for the treatment of rapid-cycling bipolar affective disorder.  Acta Psychiatr Scand. 1991;  83 456-459
    PubMedGoogle Scholar
  • 69 Joyce P R. Carbamazepine in rapid cycling bipolar affective disorder.  Int Clin Psychopharmacol. 1988;  3 123-129
    PubMedGoogle Scholar
  • 70 Okuma T. Effects of carbamazepine and lithium on affective disorders.  Neuropsychobiology. 1993;  27 138-145
    PubMedGoogle Scholar
  • 71 Denicoff K D, Smith-Jackson E E, Disney E R, Ali S O, Leverich G S, Post R M. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder.  J Clin Psychiatry. 1997;  58 470-478
    PubMedGoogle Scholar
  • 72 Greil W, Kleindienst N, Erazo N, Müller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder.  J Clin Psychopharmacol. 1998;  18 455-460
    CrossrefPubMedGoogle Scholar
  • 73 Hesslinger B, Normann C, Langosch J M, Klose P, Berger M, Walden J. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients.  J Clin Psychopharmacol. 1999;  19 310-315
    CrossrefPubMedGoogle Scholar
  • 74 Calabrese J R, Bowden C L, Sachs G S, Ascher J A, Monaghan E, Rudd G. et al . A double-blind placebo-controlled study of lamatrigine monotherapy in outpatients with bipolar I depression.  J Clin Psychiatry. 1999;  60 79-88
    CrossrefPubMedGoogle Scholar
  • 75 Fatemi S H, Rapport D J, Calabrese J R, Thuras P. Lamotrigine in rapid-cycling bipolar disorder.  J Clin Psychiatry. 1997;  58 522-527
    PubMedGoogle Scholar
  • 76 Calabrese J R, Fatemi S H, Woyshville M J. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder [letter].  Am J Psychiatry. 1996;  153 1236
    PubMedGoogle Scholar
  • 77 Kusumakar V, Yatham L N. Lamotrigine treatment of rapid cycling bipolar disorder.  Am J Psychiatry. 1997;  154 1171-1172
    PubMedGoogle Scholar
  • 78 Walden J, Schaerer L O, Schlösser S, Grunze H. An open longitudinal study of patients with bipolar rapid cycling treated with lithium or lamotrigine for mood stabilization.  Bipolar disorders. 2000;  2 336-339
    CrossrefPubMedGoogle Scholar
  • 79 Walden J, Hesslinger B, van Calker D, Berger M. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder.  Pharmacopsychiatry. 1996;  29 193-195
    PubMedGoogle Scholar
  • 80 Labbate L A, Rubey R N. Lamotrigine for treatment-refractory bipolar disorder.  Am J Psychiatry. 1997;  154 1317
    PubMedGoogle Scholar
  • 81 Fogelson D L, Sternbach H. Lamotrigine treatment of refractory bipolar disorder.  J Clin Psychiatry. 1997;  58 271-273
    PubMedGoogle Scholar
  • 82 Kusumakar V, Yatham L N. An open study of lamotrigine in refractory bipolar depression.  Psychiatry Res. 1997;  72 145-148
    CrossrefPubMedGoogle Scholar
  • 83 Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness.  J Clin Psychopharmacol. 1997;  17 185-189
    CrossrefPubMedGoogle Scholar
  • 84 Bowden C L, Calabrese J R, McElroy S L, Rhodes L J, Keck P E, Cookson J. et al . The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder.  Biol Psychiatry. 1999;  45 953-958
    PubMedGoogle Scholar
  • 85 Calabrese J R, Suppes T, Bowden C L, Sachs G S, Swann A, McElroy S L. et al . A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid cycling bipolar disorder.  J Clin Psychiat. 2000;  61 841-850
    Google Scholar
  • 86 Stancer H C, Persad E. Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine. Clinical observations.  Arch Gen Psychiatry. 1982;  39 311-312
    PubMedGoogle Scholar
  • 87 Hurowitz G I, Liebowitz M R. Antidepressant-induced rapid cycling: six case reports.  J Clin Psychopharmacol. 1993;  13 52-56
    PubMedGoogle Scholar
  • 88 Leibow D. L-thyroxine for rapid-cycling bipolar illness.  Am J Psychiatry. 1983;  140 1255
    PubMedGoogle Scholar
  • 89 Joffe R T, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants.  Psychiatry Res. 1990;  32 241-251
    CrossrefPubMedGoogle Scholar
  • 90 Gyulai L, Jaggi J, Bauer M S, Younkin S, Rubin L, Attie M. et al . Bone mineral density and L-thyroxine treatment in rapidly cycling bipolar disorder.  Biol Psychiatry. 1997;  41 503-506
    CrossrefPubMedGoogle Scholar
  • 91 Rudas S, Schmitz M, Pichler P, Baumgartner A. Treatment of refractory chronic depression and dysthymia with high-dose thyroxine.  Biol Psychiatry. 1999;  45 229-233
    CrossrefPubMedGoogle Scholar
  • 92 Dubovsky S L, Franks R D. Intracellular calcium ions in affective disorders: a review and an hypothesis.  Biol Psychiatry. 1983;  18 781-797
    PubMedGoogle Scholar
  • 93 Walden J, Grunze H, Olbrich H, Berger M. Bedeutung von Kalziumionen und Kalziumantagonisten bei affektiven Psychosen.  Fortschr Neurol Psychiatr. 1992;  60 471-476
    PubMedGoogle Scholar
  • 94 Grunze H, Schlösser S, Amann B, Walden J. Anticonvulsant drugs in bipolar disorder.  Dialogues in Clinical Neuroscience. 1999;  1 24-40
    PubMedGoogle Scholar
  • 95 Manna V. Disturbi affettivi bipolari e ruolo del calcio intraneuronale. Effetti terapeutici del trattamento con sali di litio e/o calcio antagonista in pazienti con rapida inversione di polarita.  Minerva Med. 1991;  82 757-763
    PubMedGoogle Scholar
  • 96 Grunze H, Walden J, Wolf R, Berger M. Combined treatment with lithium and nimodipine in a bipolar I manic syndrome.  Prog Neuropsychopharmacol Biol Psychiatry. 1996;  20 419-426
    CrossrefPubMedGoogle Scholar
  • 97 Pazzaglia P J, Post R M, Ketter T A, George M S, Marangell L B. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation.  Psychiatry Res. 1993;  49 257-272
    CrossrefPubMedGoogle Scholar
  • 98 Davanzo P A, Krah N, Kleiner J, McCracken J. Nimodipine treatment of an adolescent with ultradian cycling bipolar affective illness.  J Child Adolesc Psychopharmacol. 1999;  9 51-61
    PubMedGoogle Scholar
  • 99 Soares J C, Mallinger A G, Gershon S. The role of antipsychiatric agents in the treatment of bipolar disorder patients.  Int Clin Psychopharmacol. 1997;  12 65-76
    PubMedGoogle Scholar
  • 100 Gelenberg A J, Hopkins H S. Antipsychotics in bipolar disorder.  J Clin Psychiatry. 1996;  57 Suppl 9 49-52
    PubMedGoogle Scholar
  • 101 Tohen M, Zarate C A. Antipsychotic agents and bipolar disorder.  J Clin Psychiatry. 1998;  59 Suppl 1 38-48
    PubMedGoogle Scholar
  • 102 Zarate C A, Tohen M, Banov M D, Weiss M K, Cole J O. Is clozapine a mood stabilizer?.  J Clin Psychiatry. 1995;  56 108-112
    PubMedGoogle Scholar
  • 103 Zarate C A, Tohen M, Baldessarini R J. Clozapine in severe mood disorders.  J Clin Psychiatry. 1995;  56 411-417
    PubMedGoogle Scholar
  • 104 Calabrese J R, Kimmel S E, Woyshville M J, Rapport D J, Faust C J, Thompson P A. et al . Clozapine for treatment-refractory mania.  Am J Psychiatry. 1996;  153 759-764
    CrossrefPubMedGoogle Scholar
  • 105 Kimmel S E, Calabrese J R, Woyshville M J, Meltzer H Y. Clozapine in treatment-refractory mood disorders.  J Clin Psychiatry. 1994;  55 Suppl B 91-93
    PubMedGoogle Scholar
  • 106 Suppes T, McElroy S L, Gilbert J, Dessain E C, Cole J O. Clozapine in the treatment of dysphoric mania.  Biol Psychiatry. 1992;  32 270-280
    CrossrefPubMedGoogle Scholar
  • 107 Calabrese J R, Meltzer H Y, Markovitz P J. Clozapine prophylaxis in rapid cycling bipolar disorder.  J Clin Psychopharmacol. 1991;  11 396-397
    PubMedGoogle Scholar
  • 108 Suppes T, Phillips K A, Judd C R. Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: a report of three cases.  Biol Psychiatry. 1994;  36 338-340
    CrossrefPubMedGoogle Scholar
  • 109 Vieta E, Gasto C, Escobar R. Treatment of dysphoric mania with risperidone.  Int J Neuropsychopharmacol. 1995;  10 491-492
    PubMedGoogle Scholar
  • 110 Vieta E, Gasto C, Colom F, Martinez A, Otero A, Vallejo J. Treatment of refractory rapid cycling bipolar disorder with risperidone.  J Clin Psychopharmacol. 1998;  18 172-174
    CrossrefPubMedGoogle Scholar
  • 111 Bauer M S, McBride L, Chase C, Sachs G, Shea N. Manual-based group psychotherapy for bipolar disorder: a feasibility study.  J Clin Psychiatry. 1998;  59 449-455
    PubMedGoogle Scholar
  • 112 Cochran S D. Preventing medical noncompliance in the outpatient treatment of bipolar affective disorders.  J Consult Clin Psychol. 1984;  52 873-878
    CrossrefPubMedGoogle Scholar
  • 113 Frank E, Swartz H A, Mallinger A G, Thase M E, Weaver E V, Kupfer D J. Adjunctive psychotherapy for bipolar disorder: effects of changing treatment modality.  J Abnorm Psychol. 1999;  108 579-587
    CrossrefPubMedGoogle Scholar
  • 114 Perry A, Tarrier N, Morriss R, McCarthy E, Limb K. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment.  BMJ. 1999;  318 149-153
    PubMedGoogle Scholar
  • 115 Satterfield J M. Adjunctive cognitive-behavioral therapy for rapid-cycling bipolar disorder: an empirical case study.  Psychiatry. 1999;  62 357-369
    PubMedGoogle Scholar
  • 116 Roy-Byrne P P, Post R M, Uhde T W, Porcu T, Davis D. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH.  Acta Psychiatr Scand Suppl. 1985;  317 1-34
    PubMedGoogle Scholar
  • 117 Gregory S, Shawcross C R, Gill D. The Nottingham ECT Study. A double-blind comparison of bilateral, unilateral and simulated ECT in depressive illness.  Br J Psychiatry. 1985;  146 520-524
    PubMedGoogle Scholar
  • 118 Black D W, Winokur G, Nasrallah A. Treatment of mania: a naturalistic study of electroconvulsive therapy versus lithium in 438 patients.  J Clin Psychiatry. 1987;  48 132-139
    PubMedGoogle Scholar
  • 119 Grunze H, Erfurth A, Schäfer M, Amann B, Meyendorf R. Elektrokonvulsionstherapie in der Behandlung der schweren Manie.  Nervenarzt. 1999;  70 662-667
    CrossrefPubMedGoogle Scholar
  • 120 Berman E, Wolpert E A. Intractable manic-depressive psychosis with rapid cycling in an 18-year-old woman successfullly treated with electroconvulsive therapy.  J Nerv Ment Dis. 1987;  175 236-239
    PubMedGoogle Scholar
  • 121 Mosolov S N, Moshchevitin S I. Primenenie elektrosudorozhnoi terapii dlia obryva kontinual' - nogo techeniia terapevticheski rezistentnykh affektivnogo i shizoaffektivnogo psikhozov.  Zh Nevropatol Psikhiatr Im S S Korsakova. 1990;  90 121-125
    PubMedGoogle Scholar
  • 122 Devanand D P, Sackeim H A, Decina P, Prudic J. The development of mania and organic euphoria during ECT.  J Clin Psychiatry. 1988;  49 69-71
    PubMedGoogle Scholar
  • 123 Chouinard G, Beauclair L, Geiser R, Etienne P. A pilot study of magnesium aspartate hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients.  Prog Neuropsychopharmacol Biol Psychiatry. 1990;  14 171-180
    CrossrefPubMedGoogle Scholar
  • 124 Stoll A L, Sachs G S, Cohen B M, Lafer B, Christensen J D, Renshaw P F. Choline in the treatment of rapid-cycling bipolar disorder: clinical and neurochemical findings in lithium-treated patients.  Biol Psychiatry. 1996;  40 382-388
    CrossrefPubMedGoogle Scholar
  • 125 Bowden C L, Brugger A M, Swann A C, Calabrese J R, Janicak P G, Petty F. et al . Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group.  JAMA. 1994;  271 918-924
    CrossrefPubMedGoogle Scholar
  • 126 Wehr T A, Goodwin F K. Can antidepressants cause mania and worsen the course of affective illness?.  Am J Psychiatry. 1987;  144 1403-1411
    PubMedGoogle Scholar
  • 127 McElroy S L, Suppes T, Keck P E, Frye M A, Denicoff K D, Altshuler L L. et al . Open-label adjunctive topiramate in the treatment of bipolar disorders.  Biol Psychiatry. 2000;  47 1025-1033
    CrossrefPubMedGoogle Scholar
  • 128 Novac A. Atypical antipsychotics as enhancement therapy in rapid cycling mood states: a case study.  Ann Clin Psychiatry. 1998;  10 107-111
    CrossrefPubMedGoogle Scholar
  • 129 Pazzaglia P J, Post R M, Ketter T A, Callahan A M, Marangell L B, Frye M A. et al . Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness.  J Clin Psychopharmacol. 1998;  18 404-413
    CrossrefPubMedGoogle Scholar

Dr. B. Amann

Psychiatrie LMU

Nussbaumstr. 7

80336 München

Email: benedikt.amann@psy.med.uni-muenchen.de